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Abstract
Background: Cancer, heart failure and stroke are among the most common causes of death worldwide.
Investigation of the prognostic impact of each disease is important, especially for a better understanding of
competing risks. Aim of this study is to provide an overview of long term survival of cancer, heart failure and
stroke patients based on the results of large population- and hospital-based studies.
Methods: Records for our study were identified by searches of Medline via Pubmed. We focused on observed and
relative age- and sex-adjusted 5-year survival rates for cancer in general and for the four most common
malignancies in developed countries, i.e. lung, breast, prostate and colorectal cancer, as well as for heart failure and
stroke.
Results: Twenty studies were identified and included for analysis. Five-year observed survival was about 43% for all
cancer entities, 40-68% for stroke and 26-52% for heart failure. Five-year age and sex adjusted relative survival was
50-57% for all cancer entities, about 50% for stroke and about 62% for heart failure. In regard to the four most
common malignancies in developed countries 5-year relative survival was 12-18% for lung cancer, 73-89% for
breast cancer, 50-99% for prostate cancer and about 43-63% for colorectal cancer. Trend analysis revealed a survival
improvement over the last decades.
Conclusions: The results indicate that long term survival and prognosis of cancer is not necessarily worse than
that of heart failure and stroke. However, a comparison of the prognostic impact of the different diseases is limited,
corroborating the necessity for further systematic investigation of competing risks.
Background
The facts that multiple diseases are present in many
patients and that this trend is expected to increase in
the future due to population ageing reveal the necessity
for a better understanding of competing risks. Among
the diseases with high mortality cancer, heart failure and
stroke represent major global healthcare problems.
Cancer is the second most common cause of death
after cardiovascular diseases. According to the World
Health Organization (WHO), more than 10 million peo-
ple are diagnosed with cancer yearly. The disease is
responsible for 6 million deaths per year accounting for
up to 12% of all cases. Fifty six percent of newly diag-
nosed cancer patients are >65 years, while about 70% of
cancer deaths are in this age group. The median age of
cancer patients at death for both sexes ranges from 71
to 77 years [1]. The four most common malignancies in
developed countries are lung, breast, prostate, and
colorectal cancer. These account for nearly half of all
incident cases and cancer deaths of the total European
cancer burden [2]. The most common entity overall and
the leading cause of cancer related mortality is lung can-
cer. Worldwide about 1.35 million new cases and about
1.18 million deaths are estimated annually [3]. Among
women the most common entity in developed countries
is breast cancer. The disease is diagnosed in about 1.2
million patients and accounts for about 500,000 deaths
yearly in the world [4]. Prostate cancer represents the
most common cancer in men in developed countries
with estimations for 2007 revealing about 782,600 new
cases and 254,000 deaths [5,6]. Finally colorectal cancer
is the third most common malignancy worldwide with
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the WHO estimating about 945,000 new cases and
492,000 deaths annually [7].
Heart failure is a growing cause of morbidity and
mortality among cardiovascular diseases, with increas-
ing prevalence in recent years [8]. Despite significant
improvements, the disease continues to represent an
enormous clinical challenge. Currently, about 5 million
patients are suffering in the USA from heart failure,
while more than 550,000 are diagnosed yearly [9]. Inci-
dence of the disease approaches 10 per 1000 popula-
tion after age 65 and mortality was about 300,000
cases in 2006 in the USA [10]. About 80% of patients
with new diagnosed heart failure are >65 years old and
50% are >75 years old. The disease is currently one of
the most frequent causes of hospitalization, with
the annual number in the USA estimated to be over
1 million [11].
The third leading cause of death in developed coun-
tries represents cerebrovascular disease. In 2002, stroke
was the cause of 5.5 million deaths worldwide, account-
ing for about 10% of total deaths. The prevalence of
stroke in the USA is over 700,000 cases per year [12].
About 75% of all first stroke events occur after the age
of 65 years [13]. The disease is associated with high
mortality in the acute phase [14]. The annual risk of
death after stroke is about 10% [15,16], while the annual
recurrence risk is 5% per year, similar to that seen in
patients with coronary events [17].
Aim of the present article is to provide an overview of
long-term survival of cancer, heart failure and stroke
patients, based on the results of large locoregional and
international studies. The choice of those diseases in
our analysis is based on the epidemiological data con-
cerning incidence, prevalence and mortality that under-
line the high impact of cancer, heart failure and stroke
in public health and show that the diseases tend to
affect patients of similar age.
Methods
Search strategy
We identified published studies investigating long-term
survival of cancer, heart failure and stroke patients after
diagnosis in different developed countries using electro-
nic search strategies. The reference lists of identified
articles were also screened and experts in the field were
contacted. The comprehensive literature search was per-
formed between February and August 2009.
Records for our study were identified by searches of
MEDLINE via PubMed. Key-words used were “long-
term survival”, “5-year relative survival”, “breast cancer”,
“prostate cancer”, “colorectal cancer”, “lung cancer”,
“heart failure”, and “stroke”. The key-words were com-
bined using the Boolean operator “and” between survival
and diagnosis type keywords.
Study selection criteria
We included large, population-based and hospital-based
studies from developed countries that reported observed
five-year survival and/or age- and sex adjusted five-year
relative survival rates of the four most frequent cancer
entities in developed countries, i.e. lung, breast, prostate
and colorectal cancer, heart failure and stroke after first
diagnosis. Included were studies published between
2003 and 2009. All languages and types of publications
were considered eligible.
We excluded review articles and studies that investi-
gated long-term survival restricted to a specific stage of
the disease, or patients who received a specific treat-
ment. Excluded were also studies investigating a specific
patient collective, i.e. patients living under specific socio-
economic circumstances as well as studies investigating
collectives of less than 200 patients. Furthermore,
studies with short follow-up period (shorter than
5 years) and studies with unclear characteristics and
methodology, i.e. studies which did not report the meth-
ods used for evaluation of long-term survival, such as
follow-up of the collective or methodology of statistical
analysis were excluded.
Data extraction and assessement of methodological
quality
One reviewer (VA) screened all titles and abstracts to
determinate whether the research article fulfilled the
inclusion criteria. Full reports from the selected articles
were retrieved by two reviewers (VA and CT) using the
same criteria as for the initial selection. Data extracted
included demographic characteristics, study period,
identifying information and focus of the study. Primary
endpoint was 5-year observed and/or 5-year age- and
sex adjusted relative survival.
Methodological quality of the selected studies was
assessed by two reviewers (VA and CT). Primary item
used to assess study quality was the methodology
applied for the determination of long-term survival. The
applied methodology was deemed appropriate when fol-
low-up was adequately completed for a time period of
at least 5 years after first ever diagnosis and when
survival calculation was based on period analysis metho-
dology. Relative survival estimates were calculated as the
ratio of observed to expected survival, based on
calendar-year, sex and age specific life tables.
Results
Identification of studies and study characteristics
A flow diagram of the study selection process is pre-
sented in Figure 1. At the end of the selection process
20 unique citations were identified to fulfill inclusion
criteria. Those citations were identified by the electronic
search strategy and are published in peer-reviewed
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journals in the years 2003-2009. Five-year observed and/
or five-year relative survival was investigated after diag-
nosis or first hospitalization for each disease. An over-
view of the characteristics and the results of the studies
included in the analysis is presented in Additional file 1.
Special aspects of the included studies are presented in
the next paragraphs.
Long-term survival in cancer patients
Long-term survival for cancer patients in Europe has
been extensively investigated within the EUROCARE
series [18-20]. Recently, the results of the EUROCARE-4
study, analyzing long-term survival of about 3 million
adult cancer patients diagnosed in 1995-1999, were pub-
lished [21]. Data for the population were obtained from
82 cancer registries from 23 European countries.
Women had a better outcome, with 5-year observed and
relative survival of 50 and 58.2%, respectively (36.8 and
45.9% for men). Among all patients aged 65-74 years,
the observed 5-year survival was 41.3%; the value for
patients >75 years was 24.1%. Five-year relative survival
was 48.1% for the age group 65-74 years and 40.1% for
patients >75 years.
Gondos et al analyzed data from the Saarland Cancer
Registry in Germany. Five-year relative survival was
53.9% for patients aged 65-74 years and 47.1% for
Figure 1 Flow diagram of the study selection process.
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patients >75 years. The same study revealed an
increased 5-year relative survival over time from 42.2%
in 1979-1983 to 56.7% in 1999-2003 [22].
Lung cancer
In the EUROCARE-4 study, 5-year observed and relative
survivals were 9.5 and 11.2%, respectively for patients
aged 65-74 years and 4.3 and 7.0% respectively for
patients >75 years. A comparison with data from the
EUROCARE-3 study (1990-1994) showed that survival
has remained essentially unchanged [21].
In the study by Gondos et al [22] 5-year relative survi-
val was 16.6 and 17% for the age groups 65-74 and >75
years, respectively. Compared to the period 1979-1983, a
modest improvement in survival was identified.
Another study from the same group compared age-
adjusted 5-year relative survival for 23 common forms
of cancer between patients in Germany and the USA.
Comparing the results of patients with lung cancer trea-
ted in Germany and patients treated in the USA from
2000 to 2002, similar results were found [23]. Grivaux
et al presented the results of an epidemiological study
including all new cases of histologically confirmed lung
cancer managed in general hospitals in France. The
study revealed 5-year observed survival of 10.4%. The
median survival of the deceased patients was 7 months
[24].
Breast cancer
In the EUROCARE-4 study, 5-year observed and relative
survival in patients aged 65-74 years were 72.4% and
80%, respectively. Even in older patients (>75 years)
observed and relative 5-year survival rates were high
(46.7% and 72%, respectively). The study revealed
between-country survival differences with the highest
age standardized 5-year relative survival in northern
Europe countries (approximately 82%). Compared to the
EUROCARE-3 study, an increasing survival trend was
identified. Particularly, the mean European age- and
area-standardized 5-year relative survival was 76% for
the period 1990-1994 and 79% for the period 1995-1999
[21].
One of the first studies to provide a global comparison
of cancer survival was the CONCORD study. The CON-
CORD study analyzed data from 101 population-based
cancer registries from 31 countries. Within this study,
age-standardized 5-year relative survival varied between
different regions. The highest value was 83.7% for North
America. Within the USA, 5-year relative survival ran-
ged from 77.4% to 89.3%, while in Europe values varied
from 57.9% to 82%. Among the 17 USA populations
included in the study, survival was lower in blacks than
in whites (70.9 vs 84.7%, respectively) [25].
Within the Michigan Cancer Surveillance Program,
Meliker et al showed higher survival rates for the white
population [26]. The racial disparity is confirmed by the
results of other studies, revealing average 5-year survival
rates of 78% for black and about 90% for white women
with breast cancer in the USA [27].
Prostate cancer
In the EUROCARE-4 study, 5-year observed and relative
survival for patients aged 65-74 years were 66.9% and
81.1% and for patients aged 75-84 years 44.2% and
70.9%, respectively. Five-year age-standardized relative
survival varied between European countries from 48% to
about 87%. A trend towards improved 5-year survival
was identified comparing age-standardized values of 65%
in the EUROCARE-3 and 76% in the EUROCARE-4
study [21].
The CONCORD study revealed major regional differ-
ences in 5-year relative survival, especially in Europe. A
race-specific analysis in the United States showed a
higher survival rate for white (92.4%) than for black
patients (85.8%) [25].
Gondos et al showed 5-year relative survival rates of
90.5% and 80.3% for patients aged 65-74 and >75 years,
respectively. Compared to the period 1979-1983,
improved survival rates were demonstrated [22].
The same group compared the results of prostate can-
cer patients in Germany and the USA. Age adjusted 5-
year relative survival was 86.8% in Germany and 99.7%
in the USA. According to the authors, this result could
be explained by differences in screening intensity
between the two countries [23].
Survival improvement over time was shown in a retro-
spective population-based study of prostate cancer cases
reported to the Singapore Cancer Registry from 1968 to
2002. This study, performed by Chia et al, revealed a
7.9% increase in 5-year relative survival for 1998-2002
compared to 1978-1982 [28].
Colorectal cancer
Within the EUROCARE-4 study, observed and relative
5-year survival was 46.6% and 54.3% for patients aged
65-74 years; for older patients (>75 years) the respective
values were 28.5% and 47.6% [21].
In the study by Gondos et al [22] 5-year relative survi-
val for all ages was 60% for colon cancer and 59.2% for
rectal cancer, showing an increase of 16.3% and 19.5%,
respectively, compared to previous time periods. In the
second study by this group [23], patients in USA were
found to have a moderately higher relative survival in all
age groups compared to patients from Germany.
Survival analysis of patients with colorectal cancer in
Sweden was performed by Birgisson et al, demonstrating
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a trend to improved relative survival rates for both
colon and rectal cancer [29].
The CONCORD study revealed variability in colorec-
tal cancer survival between different countries. The
same study revealed racial disparities, with black popula-
tions having lower survival rates than white populations
[25].
Long-term survival for heart failure
Jhund et al investigated the long-term trends after first
hospitalization for heart failure. The 5-year case-fatality
rate for the entire patient population was 74%. Investi-
gation of the trend over time revealed an outcome
improvement. Five-year age-adjusted case fatality
decreased from 73.7% to 65.8% in men and from 69.5%
to 63.6% in women between 1986 and 1999 [30].
In a study by Blackledge et al, more than 60% of the
patients were older than 75 years. Five-year all cause
and cardiovascular survival for all patients were 27%
and 41.8%, respectively. For the subpopulation of
patients with heart failure as a primary diagnosis, 5-year
all cause and cardiovascular survival were 24.4% and
37.9%, respectively. After six years of follow up, case
fatality was 75-80% with worse outcome for patients
with heart failure as a primary diagnosis [31].
Mahjoub et al investigated the long-term prognosis of
patients with first heart failure episode in the Somme
Department (France) during 2000. Five-year observed
survival rates were 19% for octogenarians and 52% for
younger patients, while 5-year relative survival for octo-
genarians and younger patients were 40 and 62%,
respectively [32].
A study from the same region by Tribouilloy et al
showed that 5-year survival for heart failure patients
with preserved ejection fraction was equivalent to that
of patients with reduced ejection fraction (43 vs. 46%,
respectively) [33].
Similar results for patients with preserved and reduced
ejection fraction were demonstrated by Owan et al;
observed 5-year survival rates were 35 and 32%, respec-
tively [34]. Thus, within two decades, improved pharma-
cological treatment and device technology increased
survival of heart failure patients by 1 year, but 65% of
all heart failure patients still died within 5 years.
Long-term survival for stroke
Bravata et al investigated long term mortality in a
cohort of patients aged >65 years who had been dis-
charged with a primary diagnosis of acute ischemic
stroke, transient ischemic attack, or carotid stenosis
from Connecticut acute care hospitals in 1995. Annual
mortality rate was 20.2% for the first year and decreased
to about 12% for years 2-5. The authors showed that
mortality rates depended on cerebrovascular diagnosis.
Particularly, 5-year survival rate was 61.7% for carotid
stenosis, 50.4% for TIA, and 40% for acute ischemic
stroke [35].
Kim et al investigated long-term survival after first
stroke in a nationally representative inpatient sample in
Korea. Six-year survival rate was 65%. The most com-
mon causes of death were stroke and cardiovascular dis-
eases, which were found to be responsible for 65.9% of
deaths at 6-year follow-up [36].
Subanalysis of the results of a study performed by
Reggiani et al revealed age and affected brain region as
important prognostic factors. Five-year survival was
66.1% for patients aged 65-74 years and 49.4% for
patients aged 75-84 years [37].
Vernino et al investigated mortality in patients after
first cerebral infarction between 1985 and 1989. Most
frequent causes of death were cardiovascular events
(22%), respiratory infection (21%), and initial stroke
complications (14%), while cancer accounted for 7.5% of
deaths [38].
A retrospective study on patients with first ever stroke
from 1996 to 1998 carried out by Cheung et al revealed
5-year mortality rates of 56.1% for patients with intra-
cerebral haemorrhage and 33% for patients with
ischemic stroke [39].
A population-based study investigating long-term sur-
vival after first ever stroke in Australia showed a 10-year
cumulative risk of death of 79%. For the 10 years of fol-
low-up, all patients had an about 3-times-greater risk of
dying compared with individuals of the same age and
sex in the general population [40]. A more recent study
from the same group comparing 5-year survival and risk
of recurrent stroke for the time periods 1989-90 and
1995-96 revealed no statistically significant survival
improvement but a trend towards a smaller cumulative
risk of recurrent stroke event [41].
Discussion
Among diseases responsible for the majority of deaths
worldwide, cancer, heart failure and stroke possess lead-
ing positions. Aim of this work is to provide an over-
view of long term survival of those diseases as described
in large population- or hospital based studies from dif-
ferent developed countries. We chose cancer, heart fail-
ure and stroke for our analysis mainly because of their
epidemiological characteristics. Incidence and mortality
of the diseases demonstrate that they represent major
global healthcare problems tending to affect patients of
similar age. Furthermore, our clinical empiricism shows
that in some cases the prognostic impact of each disease
is unclear and that cancer is often considered to be the
disease with the worst prognosis.
Most identified studies investigated 5-year observed
survival for the disease of interest. In one of the largest
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population based studies, observed 5-year survival after
diagnosis was about 43% for all cancer diseases [21].
Observed 5-year survival for heart failure varied between
26% and 52% and observed survival after a stroke event
varied between 40% and 68%. However, comparison of
observed survival has major limitations. The observed
mortality rate within the cohort of interest does not
represent the mortality rate associated only with the dis-
ease of interest, but is equal to the all-cause mortality
rate in the reference population plus the excess mortal-
ity rate associated with the disease. Comparisons based
on observed survival rates between different studies are
not reliable, since they are affected by demographic dif-
ferences between the different populations. In order to
eliminate such effects calculation of relative survival
rates is more appropriate. Relative survival rate is
defined as the ratio of the observed survival rate in a
group of patients to the survival rate expected in a
group of people in the general population, who are simi-
lar to the patients with respect to all of the possible fac-
tors affecting survival at the beginning of the period,
except for the disease under study [42]. A relative survi-
val rate of 1 indicates that the mortality of the study
group does not differ from that expected in the general
population and that the mortality attributable to the dis-
ease is zero. For the calculation of relative survival rates
the expected survival is usually estimated from nation-
wide population life tables, stratified by age, sex and
calendar time. The major advantage of relative survival
is that the information on cause of death is not required
[43]. The analysis of the cancer related studies identified
in our investigation demonstrated 5-year relative survi-
val rates of 50% to 57% for all cancer entities. Differen-
cies in 5-year relative survival was demonstrated for the
different cancer entities. In particular, breast and pros-
tate cancer showed 5-year relative survival rates of 73%
to 89% and 50% to 99%, respectively, while lung cancer
showed considerably lower survival rates (12% to about
18%). This result highlights the need to educate the
patients and the general population that “cancer” is not
one disease, but an umbrella term for a number of
malignancies characterized by tissue infiltration and
metastatic dissemination but manifold symptomatology,
varying response to treatment strategies, and different
long-term prognosis.
Five-year relative survival rates for heart failure and
stroke in the studies identified in our search was about
62% and 50% respectively. A comparison to the relative
survival rates of the different cancer entities indicates
that cancer might not necessarily have a worse prog-
nosis. However, this conclusion is strongly limited by
various factors. The most important limiting parameter
is the lack of appropriate data in regard to relative survi-
val ratios for heart failure and stroke. Our search
identified only two studies for each disease, which is not
enough for safe conclusions. Furthermore, the use of
relative survival rates underlies the assumption that
patients are subject to two independent forces of mor-
tality, i.e. that attributable to the disease and that in the
general population. However, the disease of interest is
often included in the reference population, resulting in
bias of the estimation. Cancer and stroke are more clo-
sely linked to a hospital admission, while the develop-
ment of screening techniques, such as PSA-screening
for prostate cancer and mammography for breast can-
cer, has led to an earlier diagnosis of the diseases and
therefore a better identification of patients and discrimi-
nation from the reference population. In case of heart
failure, however, many patients are first diagnosed when
symptoms become severe enough to require hospitaliza-
tion. The patients that are not recognized are possibly
included in the reference population, resulting in bias of
the estimated relative survival rates.
Past studies have directly compared heart failure vs.
cancer-related survival within the same population,
showing results that are similar to the trend identified
in our comparison. A study performed by Stewart et al
investigated all patients with a first admission to any
Scottish hospital in 1991 for heart failure and the four
most common types of cancer, revealing that with the
notable exception of lung cancer, heart failure was asso-
ciated with a worse survival rate compared to other
common cancer entities [44].
Although comparison and analysis of long term survi-
val of different diseases is limited, it still can be an
important tool for a better understanding of competing
risks. The competing risks concept describes the analysis
of how mortality trends of one disease might influence
the mortality trends of another disease. To analyse this
different models are available. The model of Chiang
eliminates a specific cause in order to estimate the effect
on mortality from other causes [45], while the model of
Rothenberg is based on the assumption that mortality
from competing causes remains constant [46]. The
influence of cerebrovascular and cardiovascular disease
mortality trends on cancer mortality trends has been
analysed in various studies. Llorca et al analysed the
interrelation between cerebrovascular disease, ischemic
heart disease and cancer mortalities in Spanish women
in 1981 and 1994 using both models and showed that
although cerebrovascular and ischemic heart disease
mortality have decreased in all age groups during the
investigation period, this had not a significant impact on
cancer mortality [47]. However, investigation of compet-
ing risks usually assumes independence between the dif-
ferent causes of death. Different causes of death are
considered to be independent when they do not share
common risk factors. A prominent example of a
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common risk factor between cardiovascular, cerebrovas-
cular disease and various cancer entities is tobacco
smoking. The error that is produced by the assumption
of independence between those diseases is therefore
influenced on the smoking prevalence of the investi-
gated population and on the level of mortality from
tobacco-related cancers [47]. The results of our systema-
tic review cannot provide safe conlusions on competing
risks, since they compare long term survival of different
populations and do not provide information on risk fac-
tors that are important for analysis. Still, the competing
risks problem shows the necessity for studies investigat-
ing outcome of different diseases, especially considering
the fact that the number of multimorbid patients is
expected to increase in the future mainly due to popula-
tion ageing.
In respect to survival trends, the studies analysed here
reveal results that are moderately encouraging. Compar-
ison of long-term survival shows that the prognosis of
cancer and heart failure has modestly improved over the
last decades. However, a better understanding of the
underlying molecular mechanisms of the diseases and
their pathophysiology, leading to the development of
new diagnostic and screening methods and to innovative
therapeutic strategies, is still needed.
The comparison made here has some limitations. One
is the lack of appropriate data in regard to relative survi-
val rates of heart failure and stroke. Furthermore, most
population-based studies use administrative data from
registries and therefore miss detailed clinical informa-
tion and stage-specific analysis. Retrospective studies
with observational design are limited by inaccuracies in
the diagnosis and coding of the diseases. The results of
the analysis may be influenced by incomplete informa-
tion concerning prior diagnosis, stage, and severity of
the disease and variations in diagnostic accuracy and
therapeutic approaches. Competing health risks of
patients in clinical studies are not always fully analyzed
because the final cause of death is not precisely
reported.
Conclusions
The analysis presented in this paper provides indications
that cancer does not necessarily have a poorer prognosis
compared to other common causes of death such as
heart failure or stroke. Considering the fact that multi-
ple diseases are present in many patients and that this
trend is expected to increase in the future due to popu-
lation ageing, there is an emerged need for a systematic
investigation and statistical analysis of long term survival
of different diseases within a population, coordinated by
interdisciplinary teams. In this way, the role of compet-
ing risks will be better evaluated, which is important in
order to better understand individual prognostic factors
in multimorbid patients, prioritize the treatment of the
prognostically leading disease and optimize therapeutic
outcome.
Additional file 1: Characteristics and results of the studies
investigating 5-year survival of cancer, heart failure and stroke. N/A:
Not applicable, m: men, w: women.
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